• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(5): e19909.
Published online May 24, 2011. doi:  10.1371/journal.pone.0019909
PMCID: PMC3101219

Gene Expression Profiling and Association with Prion-Related Lesions in the Medulla Oblongata of Symptomatic Natural Scrapie Animals

Jason C. Bartz, Editor

Abstract

The pathogenesis of natural scrapie and other prion diseases remains unclear. Examining transcriptome variations in infected versus control animals may highlight new genes potentially involved in some of the molecular mechanisms of prion-induced pathology. The aim of this work was to identify disease-associated alterations in the gene expression profiles of the caudal medulla oblongata (MO) in sheep presenting the symptomatic phase of natural scrapie. The gene expression patterns in the MO from 7 sheep that had been naturally infected with scrapie were compared with 6 controls using a Central Veterinary Institute (CVI) custom designed 4×44K microarray. The microarray consisted of a probe set on the previously sequenced ovine tissue library by CVI and was supplemented with all of the Ovis aries transcripts that are currently publicly available. Over 350 probe sets displayed greater than 2-fold changes in expression. We identified 148 genes from these probes, many of which encode proteins that are involved in the immune response, ion transport, cell adhesion, and transcription. Our results confirm previously published gene expression changes that were observed in murine models with induced scrapie. Moreover, we have identified new genes that exhibit differential expression in scrapie and could be involved in prion neuropathology. Finally, we have investigated the relationship between gene expression profiles and the appearance of the main scrapie-related lesions, including prion protein deposition, gliosis and spongiosis. In this context, the potential impacts of these gene expression changes in the MO on scrapie development are discussed.

Introduction

Scrapie is a transmissible progressive neurodegenerative disease that occurs naturally in sheep and goats and constitutes one of the most widely studied models of transmissible spongiform encephalopathies (TSE) [1], a disease class that includes bovine spongiform encephalopathy (BSE) in cattle and human pathologies such as Creutzfeldt-Jakob disease and Kuru [1], [2], [3], [4]. A hallmark of all these diseases is the accumulation of an insoluble and protease-resistant isoform of the host-encoded prion protein (PrP), termed PrPSc. According to the prion hypothesis, PrPSc is the principal component of the infectious particle, which is called a prion [5].

The neuropathology of prion diseases is characterized by the appearance and accumulation of PrPSc in the brain, spongiform degeneration, neuronal loss, and the activation of glial cells [6], [7], [8], [9], [10], [11], [12], [13].

Intensive research has aimed to investigate the relationship between the accumulation of prion protein PrPSc, activation of microglia and astrocytes and the pathology of prion disease (e.g., neuronal loss) [12], [13], [14], [15]. Although several attempts have been made to understand the molecular events of these diseases [16], [17], [18], the precise molecular and cellular mechanisms that underlie prion disease pathogenesis, and even the role of PrPC in host species, remain unknown.

The pathogenesis of scrapie is strongly influenced by genetics, and certain PrP polymorphisms are associated with individual susceptibility [19], [20], [21], [22]. However, genes other than PRNP (Prion Protein) are also thought to be involved in the pathogenesis of prion diseases [23], [24].

The identification of genes that are differentially expressed during prion infection may help identify novel risk genes and assist in the discovery of the abnormal intracellular or intercellular pathways that are responsible for the pathogenesis of prion diseases. Several functional genomics studies performed in experimental scrapie-infection animal models have indicated that several genes are misregulated in the advanced phase of the infection [25], [26], [27], [28], [29], [30]; these results are not surprising because the disease is preceded by neuronal loss and is usually fatal. Only a limited number of ovine genomics and expression analysis tools and data are available, and thus far, no study has focused on the “whole genome” expression (transcriptome) variation in natural scrapie sheep.

The objectives of the present study were to identify the differentially expressed genes in the brains of scrapie-symptomatic sheep using a CVI custom designed 4×44K microarray platform and to analyze any possible relationship between scrapie-related neuropathological changes and the transcriptional activities of the identified genes.

Results

Scrapie-related lesions

The neuropathological features of scrapie were evaluated in the medulla oblongata tissue of 6 control and 7 clinical scrapie-infected sheep. Spongiosis, PrPSc deposition and GFAP immunoreactivity were consistent with the features of classical scrapie [31]. PrPSc deposition and spongiosis were only detected in the affected animals (Figure 1). Particular medullary nuclei in the obex, such as the nucleus dorsal motor of the vagus, the spinal tract of the trigeminal nerve and the solitary tract nucleus, were severely affected in the infected group. The low level of spongiosis observed in the control animals was an artifact due to the method of analysis (ImageJ). Even with the high variability observed in the scrapie group, the differences between the groups were statistically significant (P<0.01).

Figure 1
Quantitative values of PrPSc deposition, Glial fibrillary acidic protein expression as a marker for astrocytes and spongiform degeneration is shown as the mean ± standard error (A).

A generalized increase in the expression of the astroglial marker glial fibrillary acidic protein (GFAP) was observed in the brains of the scrapie-affected sheep (P<0.01). Hyperplasia and hypertrophy of the stellate GFAP-positive cells, consistent with reactive astrogliosis, was observed in the medulla oblongatas of the affected sheep.

Identification of genes in the medulla oblongata that are differentially expressed in natural scrapie

Transcriptome profiles in the medullae of sheep affected by scrapie and controls were obtained using the Central Veterinary Institute (CVI) custom 4×44K microarray, containing a custom eArray probe design from the earlier sequenced ovine tissue cDNA libraries supplemented with all of the currently available transcripts from the NCBI/EBI databases and with probes available from the Agilent ovine catalog. A total of 300 probe sets displayed statistically significant differences between the control and scrapie groups that were equal to or greater than a 2-fold change. Genes from Ovis aries are relatively poorly annotated, but after BLAST searches to publicly available databases, it was possible to identify a set of 148 known genes (Table S1) from the complete set of 300 differentially expressed genes. The microarray data have been deposited in the array express and are accessible through accession no. E-MTAB-532. To determine the gene ontology (GO) categories of the deregulated genes in the scrapie condition, we used DAVID Bioinformatics Resources 2008 [32], [33] (NIAID/NIH, USA). Based on the GO analysis, 93 genes had known functions; 40 genes were upregulated (43%), and 53 genes were downregulated (57%). The functional group with the highest number of regulated genes was the ion binding-related genes (15 genes), followed by the nucleotide binding-related genes (11 genes), the structural molecule activity genes (8 genes), the immune system-related genes (7 genes) and the ion transport-related genes (5 genes) (Table S1).

The significance of each GO term was also evaluated using an enrichment analysis, which calculates the significance of each cluster based on the proportion of differentially expressed genes that contributes to the respective cluster. The only significantly (P<0.05) deregulated cellular component GO term was the one corresponding with extracellular region proteins, including 24 deregulated genes (15.4% of the total modified known genes) with P = 1.0×10−9, of which 11 are extracellular matrix components (P = 1.7×10−7). Six GO terms related to molecular function were significantly deregulated: calcium ion binding (9 genes, P = 9.8×10−3), growth factor binding (4 genes, P = 3.0×10−3), extracellular matrix structural constituent (3 genes, 6.3×10−3), SMAD binding (3 genes, 3.7×10−3), carboxylic acid binding (3 genes, 4.8×10−2) and platelet derived growth factor binding (2 genes, P = 2.8×10−2). After clustering analysis, the animals studied were grouped according to their disease condition (Figure 2).

Figure 2
Condition trees of clustering analysis.

Validation of gene expression profiling by quantitative RT-PCR

To confirm the results of the microarray, we carried out quantitative RT-PCR using SYBR Green assays on a selected number of targets. For validation, we chose three upregulated (calpain 6 [CAPN6], galanin 1 [GALA1] and pancreatitis associated protein 1[PAP1]) and three downregulated (collagen 1 alpha 2 [COL1A2], collagen 3 alpha 1 [COL3A1] and melatonin receptor 1b [MTNR1B]) genes that had previously been reported to be associated with prion and other neurodegenerative diseases [34], [35], [36], [37], [38], [39], [40].

The quantitative RT-PCR analyses confirmed the microarray expression results (Figure 3). Differences between the control and scrapie groups were statistically significant for each of the 6 genes analyzed (P<0.05).

Figure 3
Relative mRNA levels.

Identification of neuropathology-related genes

To identify the relationship between gene expression profiles and scrapie neuropathology, a Mixed Model approach was performed using the Gene Expression Analysis with Mixed Models (GEAMM) software [41]. The program analyzes the continuous effect of scrapie related lesions, measured as PrPSc deposition, GFAP immunostaining and spongiosis, on individual gene expression. GEAMM v1.4 gives the probability of the regression coefficient obtained between gene expression and the scrapie lesions. As the reliability of microarray experiments is optimal for fold changes values higher than 1.7, we developed this analysis with genes whose expression was modified at a level equal to or higher than this proportion. We identified 357 probe sets whose expression was related to PrPSc deposition and 12 related to astrocytosis. Any probe was related with spongiosis. After BLAST searching, these probes corresponded to 98 genes, of which 94 could be linked to prion deposition and 4 could be linked to astrocytosis. Gene ontology analysis revealed genes mainly related to protein and ion binding and hydrolase activity in the association study. A list of known genes whose expression is highly correlated with PrPSc deposition and GFAP expression is indicated in Figure 4.

Figure 4
Relationship between gene expression profiles and scrapie histopathological lesions.

Validation of neuropathology-associated genes

In addition to the previously described 6 genes that were used to validate the array results, 5 additional genes were chosen for validation using quantitative RT-PCR, of which two, glutathione peroxidase 1 [GPX1] and metallothionein 2A [MT2A], were associated with prion deposition, one, pleiotrophin [PTN], was associated with GFAP expression, and two, coactosin-like 1 [COTL1] and N-acetylgalactosaminidase alpha [NAGA], were associated with prion deposition and GFAP expression. The genes were selected based on their known function in the brain or their association with other neurodegenerative diseases. Linear regression was calculated between the normalized expression values of these genes and prion deposition, GFAP immunoreactivity and spongiosis scores/rates. Four of the 6 genes previously analyzed for array validation (COL1A2, MTNR1B, PAP1 and CPN6) also displayed significant associations with prion deposition. Therefore, these genes were also included in the validation regression analysis. Table 1 indicates the posterior probability values of linear regression between the chosen genes and the neuropathology. The previously established associations were confirmed in 7 of the 9 analyzed genes.

Table 1
Confirmation of the association results for 9 genes using quantitative RT-PCR and linear regression.

Discussion

The neuropathology of prion disease is characterized by an accumulation of the pathological form of the prion protein, spongiform changes and reactive gliosis [42]. Although the lesion pattern of these diseases has been described in great depth, the precise mechanisms regulating these processes remain unknown. Genomic approaches show an extraordinary potential to uncover the molecular basis of complex mechanisms and to discover new biomarkers. A number of genomic analyses of brain tissue from rodent-adapted models of prion diseases (including CJD, scrapie and BSE) have been performed [25], [26], [27], [28], [29], [30]. However, there are fewer studies focused on the study of mRNA profiles in natural human CJD [43], bovine BSE [44] or ovine scrapie [45]. We present here for the first time the genomic expression variations of natural scrapie, using samples from natural symptomatic scrapie-affected sheep, and the correlation with scrapie-associated neuropathology.

To identify the differentially expressed genes in natural scrapie, we applied a global analysis of the overall transcriptome response in caudal medulla oblongata tissue from natural scrapie-affected sheep in a terminal stage of the clinical disease. This analysis was performed using the CVI custom 4×44K oligo-DNA microarray platform containing 13 k 60-mer oligos representing previously sequenced clones from a custom normalized cDNA library of sheep Peyer's Patch, tonsil and brain, supplemented with all publicly available transcripts from NCBI/EBI databases (unpublished data).

Statistical analysis identified 300 significantly changed probes having that met the threshold of a 2-fold change of expression compared to controls. These 300 probes could be linked to 93 genes with a known function based on gene ontology (GO) analysis. In accordance with previous reports [26], [46], the genes identified in this study were included in the following major groups: secreted extracellular proteins, lysosomal proteases, defense and immune response-related proteins and signal transduction-related genes.

The following four genes were previously described in other studies related to gene expression alteration in brains of murine scrapie: insulin-like growth factor binding protein 5, early growth response 1, ATPase Ca++ transporting cardiac muscle and aldehyde dehydrogenase [26], [30], [47]. The directions of these gene expression changes were in accordance with the changes observed in our study.

In previous studies, the ApoE protein has been proposed as a biomarker for prion diseases [48], [49], [50], [51] in addition to its role in the Alzheimer's disease pathway [52], [53]. Several studies have also reported the involvement of many members of the apolipoprotein gene family (ApoA1, ApoA4, ApoC1, ApoC2, ApoC3 and ApoD) in transmissible spongiform encephalopathies [26], [30], [54], [55]. Although the expression of these genes was not modified in our study, the ApoC4 (apolipoprotein C-IV) gene was upregulated in our scrapie samples. ApoC4 is normally primarily expressed in the liver and is involved in lipoprotein metabolism. The role of ApoC4 in the brain remains unclear, but it is thought to be involved in nerve growth, regeneration and neuronal repair. Our results indicate that this gene, a member of a family previously associated with TSEs, may also participate in scrapie-associated neuropathology and/or repair.

The microarray data also indicated a 5-fold increase in the expression of a gene similar to bovine calpain 6. This overexpression was confirmed by quantitative RT-PCR. Calpains are a family of calcium-activated intracellular cysteine proteases that are involved in many physiological events, such as proteolysis, apoptotic cell death, and necrosis [56], [57]. In agreement with our results, perturbations in the activity of other members of the calpain family (e.g., calpain 1) have been associated with the neuropathological processes contributing to Alzheimer's disease [58], [59].

Galanin (GALA1) overexpression has also been reported in Alzheimer's disease [34], [35], and it has been demonstrated that an increase of this neuropeptide impairs cognitive function [39]. In our study, the expression of GALA1 showed 7- and 11-fold increases according to the microarray and qRT-PCR analyses, respectively. This is the first time that the overexpression of this gene has been associated with prion diseases, suggesting a possible role of GALA1 in some of the behavior alterations reported in scrapie [60].

The pancreatitis-association protein I (PAP1) gene displayed high upregulation in the medullae of scrapie-affected sheep, according to both microarray and qRT-PCR data. Although PAP1 is an inflammatory protein that is specifically overexpressed in pancreatitis [61], it is elevated in the ileal Peyer's patch of lambs during the early phase of scrapie infection [62]. Moreover, the intervention of PAP1 in very early stages of Alzheimer's disease has been reported [38]. Our results confirmed the participation of PAP1 in scrapie pathogenesis, not only in the early phases of the diseases but also in the clinical stage.

The expression of the melatonin receptor 1B (MTNR1B) gene was highly downregulated in the medullae of affected animals. This finding is in agreement with the neuroprotective activities of melatonin described in Alzheimer's disease [63], [64]. Consequently, the decrease in MTNR1B gene expression could contribute to the brain damage observed in scrapie-affected brainstems.

Variations in the gene expression of different collagens have also been reported in Alzheimer's disease. Although increased levels of collagen XXV promote an Alzheimer's-like disease in mice [65], the upregulated expression of collagen VI in neurons of Alzheimer's disease brains may represent a protective mechanism [66]. In our results, three types of collagen (COL1A2, COL3A1 and COL12A1) exhibited downregulation in sheep with natural scrapie and might be related to the loss of their neuroprotective role.

Changes in the extracellular matrix (ECM) have been previously described in prion diseases [15], [67], but until now, specific studies based on collagen changes in the ECM have not been performed. Overall, collagens are not abundant in the ECM of the brain, but they are present in the vascular basement membrane [68]. The area studied includes a circumventricular organ, the area postrema, which is a structure rich in different collagen types and one of the entrances of the prion to the brain [69]. Further studies will be necessary to clarify the effects of prion infection on the synthesis of collagens.

Most microarrays reports have focused on comparisons between healthy and scrapie tissues [28], [29], [30]. However, when we analyze tissues from animals naturally infected with scrapie, the degree of lesion for each individual can be very different, even for animals included in the same group (healthy or scrapie affected). These differences could influence the individual expression profiles. In the present study, we aimed to investigate the effect of prion-related lesions on gene expression, which would contribute to the knowledge of the molecular mechanisms of scrapie neuropathology. Immunohistochemical and hematoxylin-eosin image quantification of PrPSc deposition, GFAP immunostaining and spongiosis could be considered continuous effects. We used the GAMM v1.4 software [41] to perform a Mixed Model Analysis using a Bayesian approach that allowed the establishment of associations between gene expression data and prion deposition, gliosis and spongiosis. The spongiosis, PrPSc deposits and generalized reactive gliosis observed in the medulla oblongatas of scrapie-affected animals in the present study were in accordance with previous descriptions of classical scrapie [31], [70], [71], [72], [73] and support the hypothesis that PrPSc deposition elicits a responsive glial cell proliferation and the appearance of spongiotic lesions [15], [74], [75], [76]. The increase of GFAP in affected animals was in accordance with the microarray experiment results, in which the GFAP gene was upregulated in scrapie medullae with a 1.7-fold change (data not shown in Table S1 because only genes with a FC>2 are represented). The mechanisms associated with the expression of GFAP in scrapie-affected medullae, along with the molecules involved in prion deposition or spongiform degeneration, remain unclear. The association between gene expression changes and these processes could contribute to the knowledge of their molecular pathways.

In contrast to the scrapie vs. healthy comparison study, most of the genes that displayed highly significant associations with scrapie neuropathological lesions are new candidate markers and have not been previously linked to prion diseases. This method allowed us to identify genes that could be related to prion-specific processes without the need for a high and significant difference between the controls and the infected animals. The association study revealed a high number of genes that are associated with prion deposition in the medulla oblongata. From these, the genes that showed the highest association probability were mainly involved in protein, nucleic acid and ion binding and hydrolase activity. Coactosin-like protein (CLP) shares significant homology with coactosin, an F-actin binding protein from Dictyostelium discoideum [77]. CLP mRNA is widely distributed throughout the tissue and is expressed at high levels in the placenta, lung, kidney, and peripheral blood leukocytes and at low levels in the brain, liver and pancreas [78]. Altered levels of structural proteins have been observed in neurological disorders using proteomic assays [79], [80], [81]. For example, increases of coactosin-like protein 1 (COTL1) have been reported in a proteomic analysis in Parkinson's disease that was proposed to be associated with a structural reorganization of parkinsonian substantia nigra [82]. In agreement with this, we identified a positive association between the expression of this gene and the levels of prion deposition and GFAP immunoreactivity, along with a significant overexpression in scrapie medullae (FC: 1.76) that suggests a role for this structural protein in different neuropathological processes.

Oxidative stress has been proposed to play an important role in the pathogenesis of prion disease [83]. PrPC plays an important role in anti-oxidative defense, and its deficiency increases susceptibility to oxidative stress [84]. Glutathione peroxidase is one of the major antioxidant enzymes in the detoxification of hydrogen peroxide [85], [86]. The brain is considered to have lower GPx-1 activity compared with other tissues [85]. This enzyme is abundant in activated microglia and is present at low levels in most neurons [85]. In vitro studies have indicated that the lack of GPx1 enhances the toxicity of the amyloid beta-peptide [87]. GPx-1 positive microglia are increased in Parkinson's disease and dementia with Lewy bodies, and it has been proposed that GPx-1 can participate in a cellular process to enzymatically degrade concentric Lewy bodies [88]. In accordance with that finding, we observed a positive association between the expression of this gene and prion deposition and a significant overexpression of GPx-1 in scrapie medullae (FC: 2.03). The role of this protein in prion diseases has not been previously investigated. Further analysis, including immunohistochemical determination of GPx-1 in scrapie brains or in vitro studies, would be necessary to elucidate a possible neuroprotective role of this enzyme in prion diseases.

Metallothioneins are a group of metal-binding proteins found in a variety of eukaryotic and prokaryotic species [89], [90]. The mouse MT I and II genes are coordinately regulated by metals, glucocorticoids and inflammatory stress signals [91]. It has been shown that the gene coding for MT II is overexpressed in the brains of scrapie-infected hamsters [92], [93], mice [94] and BSE-affected medulla oblongata [90]. Immunoreactivity for MT II has been detected consistently in the astrocytes of BSE cases [90]. The labeling for this protein has also been reported in natural scrapie [15], particularly in the brain stem and thalamus, not only in astrocytes and amoeboid-shaped glial cells but also in neuronal perykaria. In accordance with this finding, we observed a significant overexpression of the metallothionein 2A (MT2A) gene in scrapie medullae (Table 1), which was positively associated with prion deposition but not with GFAP immunostaining.

N-acetylgalactosaminidase alpha (NAGA) cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Kanzaki disease, which may involve neurologic complications in the CNS and peripheral nervous system [95]. In the present study, we observed a slight but significant increase of NAGA expression in scrapie medullae and a positive association between the expression of this gene and both prion deposition and astrogliosis. To our knowledge, this is the first time that modifications in this gene have been reported in prion diseases.

In conclusion, our genomic analysis allowed the identification of new genes involved in the neuropathology of natural scrapie in the medulla oblongata and the confirmation of genes that were previously described as biomarkers of other neurodegenerative diseases, such as Alzheimer's and Creutzfeldt-Jakob disease in humans. Likewise, as recently reported [96], [97], our findings confirm the depth of the relationship between scrapie and other neurodegenerative diseases. In addition, our association analysis contributes to the knowledge of the molecular mechanisms underlying the pathogenesis of prion diseases. Further studies of the cellular localization of the proteins coded by these differentially regulated genes are necessary to establish the specific and thus far unknown roles of these markers in TSE pathogenesis. In addition, the study of the expression of identified genes in other brain areas, as well as in preclinical scrapie infected animals, could contribute to the knowledge of their role in the disease.

Materials and Methods

Ethics Statement

This study was carried out in strict accordance with the recommendations for the care and use of experimental animals of the University of Zaragoza, in accordance with law (R.D. 1201/2005). The protocol was approved by its Committee on the Ethics of Animal Experiments (Permit Number: PI02/08).

Animals

A total of 13 Rasa Aragonesa female sheep (aged 3–5 years) were included in this study. Seven of the animals exhibited clinical signs of scrapie, and the diagnoses were made by third eyelid biopsies [60] and confirmed using the rapid test (TeEsE, Bio-Rad) and immunohistochemistry to detect PrPSc using the 6H4 monoclonal antibody [72]. We would like to emphasize that all of the sheep (n = 7) were in the terminal stage of the disease. This characterization was carried out following previously reported criteria [60], taking into account the presence of the clinical signs associated with the disease. Moreover, all of the animals belonged to flocks that had been previously characterized as scrapie-affected flocks and were located in different geographical areas. The animals were genotyped for PRNP polymorphisms as previously reported [98], and the sheep chosen for this study displayed the ARQ/ARQ genotype, which is the most susceptible genotype in this ovine breed [98]. The control animals (n = 6) were all female, belonged to the same breed, were a similar age (3 to 5 years old) and had identical PRNP genotypes (ARQ/ARQ). They were selected from flocks located in areas free of scrapie. The presence of prion protein was confirmed by immunohistochemical methods and western blotting [72].

Tissue collection and RNA isolation

Animals were sacrificed by intravenous injection of sodium pentobarbital and exsanguination, and the necropsy was performed immediately. Physical examination of the scrapie and control animals did not reveal any other pathological signs. The samples were rapidly preserved and processed according to established guidelines regarding safety. Because the lesion pattern in scrapie is bilateral, one half of the caudal medulla oblongata, including the obex, was snap-frozen in liquid nitrogen prior to long-term storage at −80°C until RNA extraction. The other half was formalin-fixed and paraffin-embedded for further histopathological analysis. Total RNA was isolated from a tissuemizer disrupted medulla oblongata in duplicate using TRIzol® (Invitrogen AG), followed by a phenol and chloroform extraction and subjected to a purification step with the NucleoSpin®RNA clean-up kit RNAII (Macherey-Nagel GmbH & Co. KG). The quality of the total RNA was assessed using the RNA 6000 Nano Assay kit and the 2100 Bioanalyzer (Agilent Technologies). The Agilent 2100 Expert software was used to estimate the RNA integrity number (RIN) index for each sample. The RIN provides a numerical assessment of the integrity of RNA that facilitates the standardization of the quality interpretation. Only high quality RNA samples with an RIN number equal to or higher than 7 were further processed for microarray analysis.

Histology and prion immunohistochemical detection

A histopathological study of the medulla oblongata at the level of the obex was performed in HE-stained slices (one from each individual control and each positive animal).

Immunohistochemical (IHC) studies were performed on adjacent sections. Positive and negative controls (omission of primary antibodies in the control and scrapie slides) were performed for every antibody.

Prion protein detection was performed following pretreatment as previously described [99]. Briefly, sections were pretreated with 98% formic acid and hydrated, autoclaving to enhance antigen retrieval. After proteinase K digestion (Roche, 4 g/ml), the sections were incubated with blocking reagent (DAKO) for 10 min to block endogenous peroxidase activity. Next, sections were incubated with the monoclonal primary antibody L42 (R-Biopharm, dilution 1[ratio]500) at RT for 30 min. Sections were processed with endogenous peroxidase blocking. The enzyme-conjugated polymer Envision (DAKO, 30 min) was used as the visualization system and DAB (DAKO, 10 min) as the chromogen. Sections were counterstained with hematoxylin.

Astrogliosis was evaluated based on glial fibrillary acidic protein (GFAP) immunostaining, as previously described [15], [16]. Briefly, after heat-induced epitope retrieval pretreatment with citrate buffer (pH 6.0), the sections were incubated for 1 h at RT with the rabbit polyclonal anti- GFAP antibody (DAKO, dilution 1[ratio]400). In routine immunoreactions, omission of the primary antibodies in control and scrapie slides served as negative controls.

The preparations were examined with a Zeiss Axioskop 40 optical microscope (Carl Zeiss AG) and a 40× magnification objective lens (Carl Zeiss AG). The images were captured with a digital camera (AxioCam MRc5, Zeiss AG) that was coupled to the microscope and a computer and were analyzed using the ImageJ 1.4.3.67 image-analysis software package (Psion Image, NIH) to determine the areas occupied by PrPSc deposition, astrogliosis and spongiosis. For the evaluation of IHC and HE slides, captured images were opened in NIH Image/ImageJ to evaluate the indices of positivity using the area method. The total area occupied by brown markers (PrP and GFAP) or by white spaces (spongiosis) was estimated by setting a “threshold” using the thresholding tool for selection of these areas and the positive IHC/HE index for that image was calculated. Significant differences between the control and scrapie groups were detected using the Student's t test.

Custom sheep oligo-DNA microarray

CVI custom 4×44K microarrays were used. They contained custom eArray designed 60-mer probes on previously sequenced normalized and subtracted cDNA libraries of ovine Peyers Patch, obex and tonsil, supplemented by the publicly available Ovis Aries transcripts from NCBI/EBI databases and by the Agilent Ovis Aries transcript catalog. All of the arrays were printed using Sureprint technology (Agilent Technologies).

Preparation of labeled cDNA and microarray hybridization

All of the procedures for the preparation of labeled cRNA probes and subsequent Genechip hybridizations were performed according to the Agilent Technologies One-Color Microarray-Based Gene Expression Analysis guidelines (http://www.home.agilent.com). First, cDNA was synthesized using 1 µg total RNA as the template and T7 Promoter Primer of Agilent One-Color RNA Spike-In (Quick Amp Kit, One-Color, Agilent Technologies). cDNA was then transcribed and labeled using T7 RNA Polymerase and cyanine 3-CTP. Finally, labeled cRNAs were cleaned up using Qiagen's RNeasy mini spin columns.

The samples were then hybridized to CVI-Agilent custom 4×44K chips. All of the hybridizations were carried out for 17 h at 65°C and 6 rpm. The chips were then washed and incubated with wash buffers following the manufacturer's protocol and scanned using the GenePix 4200AL Scanner (Axon Instruments) in conjunction with GenePix Pro 6.0 software.

Hybridizations of each sample were performed in duplicate, resulting in 14 microarrays for clinical scrapie animals and 12 for negative control animals.

Microarray Data Analysis

The hybridization data were extracted with the feature extraction 9.5.3.1 image analysis application (Agilent Technologies) before processing with GeneSpring GX 10.0.2 (Agilent Technologies). Intensity values of the chips were normalized using the 75th percentile method and the expression values were calculated. The global medulla oblongata gene expression profiles from clinical scrapie infected animals were compared to the negative controls. Furthermore, only genes with a Student's t test P-value≤0.05 and a 2-fold change as the lower limit were selected. These genes were clustered by their Euclidean distance coefficient using the Permutmatrix software [100]. A BLAST search of the GenBank database was performed to identify the genes that were similar to the differentially expressed probes. Molecular functions of the genes were classified according to Gene Ontology (GO), using on-line functional annotation of DAVID Bioinformatics Resources 2008 [32], [33] (NIAID/NIH, USA).

Relationship between neuropathology and gene expression

The relationship between neuropathological lesions and gene expression was performed using a Mixed Model Analysis under a Bayesian approach by the Gene Expression Analysis with Mixed Models (GEAMM) software [41].

The statistical model assumed the following Bayesian likelihood of logarithm of gene expression data provided by the oligo-DNA microarray:

equation image

where a is the array effect and b is the vector regression slope associated with the numerical valuation of the neuropathological changes (c: prion deposition, spongiosis or astrogliosis). Moreover, X is the incidence matrix that relates the array effects to the logarithm of gene expression data (y). Finally, R is the matrix of residual (co)variances with probe-specific residual variance and null residual covariances. Prior distributions were assumed to be flat for a, b and R. A more detailed description of the statistical procedure was presented by Casellas et al. (2008) [41].

The Bayesian analysis was performed using a Gibbs sampler approach [101] with a single chain of 500,000 iterations after discarding the first 50,000. The results with a posterior probability below 0.01 for a regression slope associated with a neuropathological lesion greater (or lower) than zero were selected.

Real-time quantitative PCR

We performed quantitative real-time RT-PCR (qRT-PCR) to confirm the expression of 6 genes that were expressed at a level higher or lower than three times in the scrapie group compared to controls in the oligo-DNA microarray expression analysis, and 8 genes that displayed the highest significance in the Mixed Model Analysis. The PCR primer sequences used for quantification of the genes encoding CAPN6 (calpain 6), COL1A2 (collagen Ia), COL3A1 (collagen IIIa), GALA1 (galanin 1), MTNR1B (melatonin receptor 1B), PAP1 (pancreatitis associated protein 1), COTL1 (coactosin-like 1), GPX1 (glutathione peroxidase 1), MT2A (metallothionein 2A), PTN (pleiotrophin) and NAGA (N-acetylgalactosaminidase, alpha) are indicated by Table 2. The quantitative PCR assays were designed using Primer Express 2.0 software (Applied Biosystems) to select appropriate primer sequences from known sheep or bovine sequences. Whenever possible, the exon–exon border was considered when designing the primers to prevent the amplification of genomic DNA in the PCR reaction. Complementary DNA (cDNA) was synthesized from 1 µg of each RNA using random hexamer primers with the Superscript First Standard Synthesis System for RT-PCR (Invitrogen). Retrotranscription with and without enzyme was performed to confirm the elimination of any remaining DNA.

Table 2
Genes analyzed by quantitative real-time PCR.

PCR reactions were performed using SYBR® Green (PE Applied Biosystems) assays. PCR amplification was performed in an ABIPrism fast 7500 Sequence Detection System (PE Applied Biosystems). All of the RT-PCR reactions were run in triplicate with total reaction volumes of 10 µl, using 10–20 ng of cDNA as template and 300 nM as the final concentration of primers. Universal conditions were used, with an initial 10 min activation and denaturation step at 95°C, followed by 40 cycles of 15 s at 95°C and 30 s at 60°C. The baseline and threshold for Ct calculation were set automatically with the ABI-Prism 7500 software Version 2.0.1. The levels of gene expression were determined using the comparative Ct method.

To improve the normalization accuracy, the geometric mean of three housekeeping genes was used to calculate the normalization factor (NF), which was used to normalize the expression level of each gene in each sample [102]. The NF was calculated from the GAPDH, G6PDH and RPL32 expression data. These genes are the three most stable reference housekeeping genes in sheep medulla oblongata and have been used as internal references for expression studies in scrapie [103]. Primers and PCR conditions for the amplification of these housekeeping genes have been previously described [103], [104].

Quantitative results obtained from qRT-PCR assays are expressed as fold change. Student's t test analyses were used to determine whether the differences observed between groups were statistically significant (P<0.05) for the 6 differentially expressed genes, and a linear regression was performed to confirm the relationship observed in the 8 genes chosen after Mixed Model Analysis.

Supporting Information

Table S1

List of differentially expressed genes in natural Scrapie medulla oblongata and their associated functions based on GO analysis. Only those genes with FC>2 and a known GO term are shown. References for differentially expressed genes previously reported in other TSEs. *Genes chosen for validation by quantitative RT-PCR.

(DOC)

Acknowledgments

The authors thank Belén Marín, Silvia Ruiz and Yolanda Gracia for her technical assistance. Also we would like to thank the Spanish Ministry of Science and Innovation (MICINN), the Spanish Ministry of Foreign Affairs and Cooperation (MAEC/AECID) and the Dutch Ministry of Agriculture, Nature Management, and Fisheries (LNV).

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was performed as part of the AGL2008-0256 project, financed by the Spanish MCIIN. Hicham Filali was supported by doctoral grants from the Ministerio de Asuntos Exteriores y de Cooperación (MAEC/AECID). Arrays and sequenced libraries were made available from projects at CVI supported by grants from the Dutch Ministry of Agriculture, Nature Management, and Fisheries (LNV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Prusiner SB. Prion diseases and the BSE crisis. Science. 1997;278:245–251. [PubMed]
2. Aguzzi A, Weissmann C, Brandner S, Raeber AJ, Klein MA, et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature. 1997;389:69–73. [PubMed]
3. Chesebro B. Human TSE disease–viral or protein only? Nat Med. 1997;3:491–492. [PubMed]
4. Bons N, Mestre-Frances N, Belli P, Cathala F, Gajdusek DC, et al. Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad Sci U S A. 1999;96:4046–4051. [PMC free article] [PubMed]
5. Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13363–13383. [PMC free article] [PubMed]
6. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86:7611–7615. [PMC free article] [PubMed]
7. Hunter N, Goldmann W, Smith G, Hope J. The association of a codon 136 PrP gene variant with the occurrence of natural scrapie. Arch Virol. 1994;137:171–177. [PubMed]
8. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996;53:913–920. [PubMed]
9. Heizmann CW, Cox JA. New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Biometals. 1998;11:383–397. [PubMed]
10. Ishisaka R, Utsumi T, Kanno T, Arita K, Katunuma N, et al. Participation of a cathepsin L-type protease in the activation of caspase-3. Cell Struct Funct. 1999;24:465–470. [PubMed]
11. Kim HC, Jhoo WK, Choi DY, Im DH, Shin EJ, et al. Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res. 1999;851:76–86. [PubMed]
12. Giese A, Kretzschmar HA. Prion-induced neuronal damage–the mechanisms of neuronal destruction in the subacute spongiform encephalopathies. Curr Top Microbiol Immunol. 2001;253:203–217. [PubMed]
13. Hur K, Kim J-I, Choi S-I, Choi E-K, Carp RI, et al. The pathogenic mechanisms of prion diseases. Mechanisms of Ageing and Development. 2002;123:1637–1647. [PubMed]
14. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, et al. Role of microglia in neuronal cell death in prion disease. Brain Pathol. 1998;8:449–457. [PubMed]
15. Vidal E, Acin C, Foradada L, Monzon M, Marquez M, et al. Immunohistochemical characterisation of classical scrapie neuropathology in sheep. J Comp Pathol. 2009;141:135–146. [PubMed]
16. Serrano C, Lyahyai J, Bolea R, Varona L, Monleon E, et al. Distinct spatial activation of intrinsic and extrinsic apoptosis pathways in natural scrapie: association with prion-related lesions. Vet Res. 2009;40:42. [PMC free article] [PubMed]
17. Siso S, Puig B, Varea R, Vidal E, Acin C, et al. Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathol. 2002;103:615–626. [PubMed]
18. Bolea R, Hortells P, Martin-Burriel I, Vargas A, Ryffel B, et al. Consequences of dietary manganese and copper imbalance on neuronal apoptosis in a murine model of scrapie. Neuropathol Appl Neurobiol. 36:300–311. [PubMed]
19. Laplanche JL, Chatelain J, Beaudry P, Dussaucy M, Bounneau C, et al. French autochthonous scrapied sheep without the 136Val PrP polymorphism. Mamm Genome. 1993;4:463–464. [PubMed]
20. Belt PB, Muileman IH, Schreuder BE, Bos-de Ruijter J, Gielkens AL, et al. Identification of five allelic variants of the sheep PrP gene and their association with natural scrapie. J Gen Virol. 1995;76(Pt 3):509–517. [PubMed]
21. Goldmann W, O'Neill G, Cheung F, Charleson F, Ford P, et al. PrP (prion) gene expression in sheep may be modulated by alternative polyadenylation of its messenger RNA. J Gen Virol. 1999;80(Pt 8):2275–2283. [PubMed]
22. Goldmann W, Hunter N, Smith G, Foster J, Hope J. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J Gen Virol. 1994;75(Pt 5):989–995. [PubMed]
23. Diaz C, Vitezica ZG, Rupp R, Andreoletti O, Elsen JM. Polygenic variation and transmission factors involved in the resistance/susceptibility to scrapie in a Romanov flock. J Gen Virol. 2005;86:849–857. [PubMed]
24. Lloyd SE, Onwuazor ON, Beck JA, Mallinson G, Farrall M, et al. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc Natl Acad Sci U S A. 2001;98:6279–6283. [PMC free article] [PubMed]
25. Dandoy-Dron F, Guillo F, Benboudjema L, Deslys JP, Lasmezas C, et al. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J Biol Chem. 1998;273:7691–7697. [PubMed]
26. Booth S, Bowman C, Baumgartner R, Sorensen G, Robertson C, et al. Identification of central nervous system genes involved in the host response to the scrapie agent during preclinical and clinical infection. J Gen Virol. 2004;85:3459–3471. [PubMed]
27. Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, et al. Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol. 2004;78:11051–11060. [PMC free article] [PubMed]
28. Brown AR, Webb J, Rebus S, Williams A, Fazakerley JK. Identification of up-regulated genes by array analysis in scrapie-infected mouse brains. Neuropathol Appl Neurobiol. 2004;30:555–567. [PubMed]
29. Riemer C, Neidhold S, Burwinkel M, Schwarz A, Schultz J, et al. Gene expression profiling of scrapie-infected brain tissue. Biochem Biophys Res Commun. 2004;323:556–564. [PubMed]
30. Skinner PJ, Abbassi H, Chesebro B, Race RE, Reilly C, et al. Gene expression alterations in brains of mice infected with three strains of scrapie. BMC Genomics. 2006;7:114. [PMC free article] [PubMed]
31. Vidal E, Bolea R, Tortosa R, Costa C, Domenech A, et al. Assessment of calcium-binding proteins (Parvalbumin and Calbindin D-28K) and perineuronal nets in normal and scrapie-affected adult sheep brains. J Virol Methods. 2006;136:137–146. [PubMed]
32. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. [PubMed]
33. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3. [PMC free article] [PubMed]
34. Counts SE, He B, Che S, Ginsberg SD, Mufson EJ. Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer's disease. Neurodegener Dis. 2008;5:228–231. [PMC free article] [PubMed]
35. Counts SE, Perez SE, Mufson EJ. Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective? Cell Mol Life Sci. 2008;65:1842–1853. [PMC free article] [PubMed]
36. Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Poeggeler B, et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res. 2002;32:135–142. [PubMed]
37. Skretting G, Austbo L, Olsaker I, Espenes A. Cloning and expression analysis of an ovine PAP-like protein cDNA, a gene differentially expressed in scrapie. Gene. 2006;376:116–122. [PubMed]
38. Duplan L, Michel B, Boucraut J, Barthellemy S, Desplat-Jego S, et al. Lithostathine and pancreatitis-associated protein are involved in the very early stages of Alzheimer's disease. Neurobiol Aging. 2001;22:79–88. [PubMed]
39. Crawley JN. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Cell Mol Life Sci. 2008;65:1836–1841. [PMC free article] [PubMed]
40. Liang Y, Diehn M, Bollen AW, Israel MA, Gupta N. Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. J Neurooncol. 2008;86:133–141. [PubMed]
41. Casellas J, Ibanez-Escriche N, Martinez-Giner M, Varona L. GEAMM v.1.4: a versatile program for mixed model analysis of gene expression data. Anim Genet. 2008;39:89–90. [PubMed]
42. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144. [PubMed]
43. Xiang W, Windl O, Westner IM, Neumann M, Zerr I, et al. Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2005;58:242–257. [PubMed]
44. Khaniya B, Almeida L, Basu U, Taniguchi M, Williams JL, et al. Microarray analysis of differentially expressed genes from Peyer's patches of cattle orally challenged with bovine spongiform encephalopathy. J Toxicol Environ Health A. 2009;72:1008–1013. [PubMed]
45. Cosseddu GM, Andreoletti O, Maestrale C, Robert B, Ligios C, et al. Gene expression profiling on sheep brain reveals differential transcripts in scrapie-affected/not-affected animals. Brain Res. 2007;1142:217–222. [PubMed]
46. Baker CA, Manuelidis L. Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A. 2003;100:675–679. [PMC free article] [PubMed]
47. Booth S, Bowman C, Baumgartner R, Dolenko B, Sorensen G, et al. Molecular classification of scrapie strains in mice using gene expression profiling. Biochem Biophys Res Commun. 2004;325:1339–1345. [PubMed]
48. Jones V, Martin TC, Keyes P, Dawson M. Protein markers in cerebrospinal fluid from BSE-affected cattle. Vet Rec. 1996;139:360–363. [PubMed]
49. Hochstrasser DF, Frutiger S, Wilkins MR, Hughes G, Sanchez JC. Elevation of apolipoprotein E in the CSF of cattle affected by BSE. FEBS Lett. 1997;416:161–163. [PubMed]
50. Choe LH, Green A, Knight RS, Thompson EJ, Lee KH. Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis. 2002;23:2242–2246. [PubMed]
51. Parveen I, Moorby J, Allison G, Jackman R. The use of non-prion biomarkers for the diagnosis of Transmissible Spongiform Encephalopathies in the live animal. Vet Res. 2005;36:665–683. [PubMed]
52. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med. 16:287–294. [PubMed]
53. Zetzsche T, Rujescu D, Hardy J, Hampel H. Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn. 10:667–690. [PubMed]
54. Wollmer MA. Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta. 1801:762–773. [PubMed]
55. Sun Y, Shi J, Zhang S, Tang M, Han H, et al. The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population. Neurosci Lett. 2005;380:219–222. [PubMed]
56. Bertipaglia I, Carafoli E. Calpains and human disease. Subcell Biochem. 2007;45:29–53. [PubMed]
57. Croall DE, Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol. 2007;8:218. [PMC free article] [PubMed]
58. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615–622. [PubMed]
59. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360–364. [PubMed]
60. Vargas F, Lujan L, Bolea R, Monleon E, Martin-Burriel I, et al. Detection and clinical evolution of scrapie in sheep by 3rd eyelid biopsy. J Vet Intern Med. 2006;20:187–193. [PubMed]
61. Orelle B, Keim V, Masciotra L, Dagorn JC, Iovanna JL. Human pancreatitis-associated protein. Messenger RNA cloning and expression in pancreatic diseases. J Clin Invest. 1992;90:2284–2291. [PMC free article] [PubMed]
62. Skretting G, Espenes A, Ulvund MJ, Olsaker I. cDNA representational difference analysis of ileal Peyer's patches in lambs after oral inoculation with scrapie. Biochem Biophys Res Commun. 2004;316:272–279. [PubMed]
63. Yang X, Yang Y, Fu Z, Li Y, Feng J, et al. Melatonin ameliorates alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol [PubMed]
64. Arushanian EB. [Melatonin and Alzheimer's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 110:100–106. [PubMed]
65. Tong Y, Xu Y, Scearce-Levie K, Ptacek LJ, Fu YH. COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo. Neurogenetics. 11:41–52. [PMC free article] [PubMed]
66. Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, et al. Collagen VI protects neurons against Abeta toxicity. Nat Neurosci. 2009;12:119–121. [PMC free article] [PubMed]
67. Costa C, Tortosa R, Domenech A, Vidal E, Pumarola M, et al. Mapping of aggrecan, hyaluronic acid, heparan sulphate proteoglycans and aquaporin 4 in the central nervous system of the mouse. J Chem Neuroanat. 2007;33:111–123. [PubMed]
68. Novak U, Kaye AH. Extracellular matrix and the brain: components and function. J Clin Neurosci. 2000;7:280–290. [PubMed]
69. Siso S, Jeffrey M, Gonzalez L. Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route. Neuropathol Appl Neurobiol. 2009;35:232–246. [PubMed]
70. Ligios C, Jeffrey M, Ryder SJ, Bellworthy SJ, Simmons MM. Distinction of scrapie phenotypes in sheep by lesion profiling. J Comp Pathol. 2002;127:45–57. [PubMed]
71. Gonzalez L, Martin S, Jeffrey M. Distinct profiles of PrP(d) immunoreactivity in the brain of scrapie- and BSE-infected sheep: implications for differential cell targeting and PrP processing. J Gen Virol. 2003;84:1339–1350. [PubMed]
72. Bolea R, Monleon E, Schiller I, Raeber AJ, Acin C, et al. Comparison of immunohistochemistry and two rapid tests for detection of abnormal prion protein in different brain regions of sheep with typical scrapie. J Vet Diagn Invest. 2005;17:467–469. [PubMed]
73. Spiropoulos J, Casalone C, Caramelli M, Simmons MM. Immunohistochemistry for PrPSc in natural scrapie reveals patterns which are associated with the PrP genotype. Neuropathol Appl Neurobiol. 2007;33:398–409. [PubMed]
74. Georgsson G, Gisladottir E, Arnadottir S. Quantitative assessment of the astrocytic response in natural scrapie of sheep. J Comp Pathol. 1993;108:229–240. [PubMed]
75. Wells GA, Sayers AR, Wilesmith JW. Clinical and epidemiological correlates of the neurohistology of cases of histologically unconfirmed, clinically suspect bovine spongiform encephalopathy. Vet Rec. 1995;136:211–216. [PubMed]
76. Brown DR. BSE did not cause variant CJD: an alternative cause related to post-industrial environmental contamination. Med Hypotheses. 2001;57:555–560. [PubMed]
77. de Hostos EL, Bradtke B, Lottspeich F, Gerisch G. Coactosin, a 17 kDa F-actin binding protein from Dictyostelium discoideum. Cell Motil Cytoskeleton. 1993;26:181–191. [PubMed]
78. Li X, Liu X, Lou Z, Duan X, Wu H, et al. Crystal structure of human coactosin-like protein at 1.9 A resolution. Protein Sci. 2004;13:2845–2851. [PMC free article] [PubMed]
79. Jin J, Hulette C, Wang Y, Zhang T, Pan C, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics. 2006;5:1193–1204. [PubMed]
80. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, et al. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics. 2006;6:3414–3425. [PubMed]
81. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics. 2004;4:3943–3952. [PubMed]
82. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 2008;6:8. [PMC free article] [PubMed]
83. Kim JI, Choi SI, Kim NH, Jin JK, Choi EK, et al. Oxidative stress and neurodegeneration in prion diseases. Ann N Y Acad Sci. 2001;928:182–186. [PubMed]
84. Brown DR. Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol. 2005;43:229–243. [PubMed]
85. Fukuhara R, Kageyama T. Tissue distribution, molecular cloning, and gene expression of cytosolic glutathione peroxidase in Japanese monkey. Zoolog Sci. 2003;20:861–868. [PubMed]
86. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med. 1999;27:951–965. [PubMed]
87. Crack PJ, Cimdins K, Ali U, Hertzog PJ, Iannello RC. Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. J Neural Transm. 2006;113:645–657. [PubMed]
88. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63–73. [PubMed]
89. Winge DR. Copper-regulatory domain involved in gene expression. Prog Nucleic Acid Res Mol Biol. 1998;58:165–195. [PubMed]
90. Hanlon J, Monks E, Hughes C, Weavers E, Rogers M. Metallothionein in bovine spongiform encephalopathy. J Comp Pathol. 2002;127:280–289. [PubMed]
91. Palmiter RD. Molecular biology of metallothionein gene expression. Experientia. 1987;Suppl 52:63–80. [PubMed]
92. Duguid JR, Rohwer RG, Seed B. Isolation of cDNAs of scrapie-modulated RNAs by subtractive hybridization of a cDNA library. Proc Natl Acad Sci U S A. 1988;85:5738–5742. [PMC free article] [PubMed]
93. Duguid JR, Dinauer MC. Library subtraction of in vitro cDNA libraries to identify differentially expressed genes in scrapie infection. Nucleic Acids Res. 1990;18:2789–2792. [PMC free article] [PubMed]
94. Diedrich JF, Bendheim PE, Kim YS, Carp RI, Haase AT. Scrapie-associated prion protein accumulates in astrocytes during scrapie infection. Proc Natl Acad Sci U S A. 1991;88:375–379. [PMC free article] [PubMed]
95. Umehara F, Matsumuro K, Kurono Y, Arimura K, Osame M, et al. Neurologic manifestations of Kanzaki disease. Neurology. 2004;62:1604–1606. [PubMed]
96. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 11:301–307. [PMC free article] [PubMed]
97. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 11:155–159. [PMC free article] [PubMed]
98. Acin C, Martin-Burriel I, Goldmann W, Lyahyai J, Monzon M, et al. Prion protein gene polymorphisms in healthy and scrapie-affected Spanish sheep. J Gen Virol. 2004;85:2103–2110. [PubMed]
99. Monleon E, Monzon M, Hortells P, Vargas A, Acin C, et al. Detection of PrPsc on lymphoid tissues from naturally affected scrapie animals: comparison of three visualization systems. J Histochem Cytochem. 2004;52:145–151. [PubMed]
100. Caraux G, Pinloche S. PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics. 2005;21:1280–1281. [PubMed]
101. Gelfand AE, Smith AFM. Sampling-Based Approaches to Calculating Marginal Densities. Journal of the American Statistical Association. 1990;85:398–409.
102. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034. [PMC free article] [PubMed]
103. Lyahyai J, Serrano C, Ranera B, Badiola JJ, Zaragoza P, et al. Effect of scrapie on the stability of housekeeping genes. Anim Biotechnol. 2010;21:1–13. [PubMed]
104. Garcia-Crespo D, Juste RA, Hurtado A. Selection of ovine housekeeping genes for normalisation by real-time RT-PCR; analysis of PrP gene expression and genetic susceptibility to scrapie. BMC Vet Res. 2005;1:3. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...